Cargando…
Mistletoe preparation (Viscum Fraxini-2) as palliative treatment for malignant pleural effusion: a feasibility study with comparison to bleomycin
BACKGROUND: Malignant pleural effusion is a common problem in patients with solid tumours. It has a significant impact on quality of life, and, hence, there is a substantial need to investigate new agents to treat it. PATIENTS AND METHODS: This is a prospective randomised controlled study, including...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004388/ https://www.ncbi.nlm.nih.gov/pubmed/24834119 http://dx.doi.org/10.3332/ecancer.2014.424 |
_version_ | 1782313969982111744 |
---|---|
author | Gaafar, Rabab Abdel Rahman, Abdel Rahman M Aboulkasem, Fatma El Bastawisy, Ahmed |
author_facet | Gaafar, Rabab Abdel Rahman, Abdel Rahman M Aboulkasem, Fatma El Bastawisy, Ahmed |
author_sort | Gaafar, Rabab |
collection | PubMed |
description | BACKGROUND: Malignant pleural effusion is a common problem in patients with solid tumours. It has a significant impact on quality of life, and, hence, there is a substantial need to investigate new agents to treat it. PATIENTS AND METHODS: This is a prospective randomised controlled study, including patients with symptomatic recurrent malignant pleural effusion of different primaries. Patients were randomised into two groups: the first group received five ampoules of mistletoe preparation with defined lectin content (Viscum Fraxini-2, ATOS Pharma) diluted in 10 cc glucose 5% solution. Re-instillation was repeated every week until complete dryness of the pleural fluid was achieved (the maximum duration of the therapy was eight weeks). The second group received 60 units of bleomycin once intrapleurally. AIMS: The primary aim of this paper was to evaluate the efficacy of mistletoe preparation as a palliative treatment for malignant pleural effusions in comparison with bleomycin. The secondary aim was to evaluate the tolerability of the mistletoe preparation. RESULTS: A total of 23 patients were included and followed up during the study from December 2007 to January 2012: 13 patients received mistletoe preparation, and ten patients received bleomycin. Overall clinical response was reported in 61.5% of the mistletoe preparation arm versus 30% in bleomycin arm (p = 0.2138), 95% CI = (–0.1203, 0.6325). The toxicity of both arms was mild and manageable; the mistletoe preparation arm included fever, chills, headache, malaise, and, in two cases, allergic reaction, which was controlled by discontinuation of the drug and steroid injection. CONCLUSION: Mistletoe preparation is an efficient and well tolerated sclerosant agent which needs further investigation. |
format | Online Article Text |
id | pubmed-4004388 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Cancer Intelligence |
record_format | MEDLINE/PubMed |
spelling | pubmed-40043882014-05-15 Mistletoe preparation (Viscum Fraxini-2) as palliative treatment for malignant pleural effusion: a feasibility study with comparison to bleomycin Gaafar, Rabab Abdel Rahman, Abdel Rahman M Aboulkasem, Fatma El Bastawisy, Ahmed Ecancermedicalscience Research BACKGROUND: Malignant pleural effusion is a common problem in patients with solid tumours. It has a significant impact on quality of life, and, hence, there is a substantial need to investigate new agents to treat it. PATIENTS AND METHODS: This is a prospective randomised controlled study, including patients with symptomatic recurrent malignant pleural effusion of different primaries. Patients were randomised into two groups: the first group received five ampoules of mistletoe preparation with defined lectin content (Viscum Fraxini-2, ATOS Pharma) diluted in 10 cc glucose 5% solution. Re-instillation was repeated every week until complete dryness of the pleural fluid was achieved (the maximum duration of the therapy was eight weeks). The second group received 60 units of bleomycin once intrapleurally. AIMS: The primary aim of this paper was to evaluate the efficacy of mistletoe preparation as a palliative treatment for malignant pleural effusions in comparison with bleomycin. The secondary aim was to evaluate the tolerability of the mistletoe preparation. RESULTS: A total of 23 patients were included and followed up during the study from December 2007 to January 2012: 13 patients received mistletoe preparation, and ten patients received bleomycin. Overall clinical response was reported in 61.5% of the mistletoe preparation arm versus 30% in bleomycin arm (p = 0.2138), 95% CI = (–0.1203, 0.6325). The toxicity of both arms was mild and manageable; the mistletoe preparation arm included fever, chills, headache, malaise, and, in two cases, allergic reaction, which was controlled by discontinuation of the drug and steroid injection. CONCLUSION: Mistletoe preparation is an efficient and well tolerated sclerosant agent which needs further investigation. Cancer Intelligence 2014-04-25 /pmc/articles/PMC4004388/ /pubmed/24834119 http://dx.doi.org/10.3332/ecancer.2014.424 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Gaafar, Rabab Abdel Rahman, Abdel Rahman M Aboulkasem, Fatma El Bastawisy, Ahmed Mistletoe preparation (Viscum Fraxini-2) as palliative treatment for malignant pleural effusion: a feasibility study with comparison to bleomycin |
title | Mistletoe preparation (Viscum Fraxini-2) as palliative treatment for malignant pleural effusion: a feasibility study with comparison to bleomycin |
title_full | Mistletoe preparation (Viscum Fraxini-2) as palliative treatment for malignant pleural effusion: a feasibility study with comparison to bleomycin |
title_fullStr | Mistletoe preparation (Viscum Fraxini-2) as palliative treatment for malignant pleural effusion: a feasibility study with comparison to bleomycin |
title_full_unstemmed | Mistletoe preparation (Viscum Fraxini-2) as palliative treatment for malignant pleural effusion: a feasibility study with comparison to bleomycin |
title_short | Mistletoe preparation (Viscum Fraxini-2) as palliative treatment for malignant pleural effusion: a feasibility study with comparison to bleomycin |
title_sort | mistletoe preparation (viscum fraxini-2) as palliative treatment for malignant pleural effusion: a feasibility study with comparison to bleomycin |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004388/ https://www.ncbi.nlm.nih.gov/pubmed/24834119 http://dx.doi.org/10.3332/ecancer.2014.424 |
work_keys_str_mv | AT gaafarrabab mistletoepreparationviscumfraxini2aspalliativetreatmentformalignantpleuraleffusionafeasibilitystudywithcomparisontobleomycin AT abdelrahmanabdelrahmanm mistletoepreparationviscumfraxini2aspalliativetreatmentformalignantpleuraleffusionafeasibilitystudywithcomparisontobleomycin AT aboulkasemfatma mistletoepreparationviscumfraxini2aspalliativetreatmentformalignantpleuraleffusionafeasibilitystudywithcomparisontobleomycin AT elbastawisyahmed mistletoepreparationviscumfraxini2aspalliativetreatmentformalignantpleuraleffusionafeasibilitystudywithcomparisontobleomycin |